Joanne Amies is an experienced Regulatory Affairs Professional with over 20 years of expertise in regulatory affairs, particularly in the fields of haematology and oncology. She has played a significant role in the approval of groundbreaking therapies in Australia, including CAR T-cell therapy and gene therapy for SMA.

Hiram Chipperfield is a life sciences professional with a focus on therapeutic product development and regulatory affairs. He holds a Ph.D. in Cell Biology from the University of Queensland which was followed by academic and commercial cell therapy research. Throughout his career, Hiram has worked across a range of therapeutic product development projects, from diagnostics to cell therapies. His expertise spans preclinical development, clinical strategy, product registration, and post-market reimbursement applications. His professional interests include the development of cell and gene therapies. As an IBC member and Chair, Hiram has reviewed over 20 GMO projects from first-in-human clinical studies through to commercial applications. In the field of cell-based therapies, he has leveraged a practical approach to regulations to support a range of therapeutic programs. Hiram has held senior roles in a diagnostics company and supported early-stage sponsors through consulting roles in several clinical CROs. He currently holds the position of Senior Manager – Regulatory Affairs at Vaxxas.